The genetics of IgA nephropathy

IgA nephropathy is the most common form of primary glomerulonephritis. Variations in clinical manifestations indicate that a diagnosis of IgA nephropathy encompasses multiple disease subsets that cannot be distinguished on the basis of renal pathology or clinical variables alone. Familial forms of the disease have been reported throughout the world, but are probably under-recognized because associated urinary abnormalities are often intermittent in affected family members. IgA nephropathy has complex determination, with different genes probably causing disease in different patient subgroups. Of the many pathogenic mechanisms reported, defects in IgA1 glycosylation that lead to formation of immune complexes have been consistently implicated. Here, we present the evidence for genetic contributions to the disease, review clinical patterns of familial disease, and summarize some of the most promising genetic studies conducted to date. Linkage-based approaches to the study of familial forms of the disease have identified significant or suggestive loci on chromosomes 6q22-23, 2q36, 4q26-31, 17q12-22 and 3p24-23, but no causal gene has yet been identified. Many interesting, but poorly replicated, genetic association studies have also been reported. We discuss recent developments in analytic tools that should enable genetic studies of sporadic forms of disease by the genome-wide association approach.     

IgA肾病的分子遗传学研究

IgA肾病是我国最为常见的原发性肾小球疾病,占原发性肾小球病的40%～47.2%,而且近年来该病的发生呈逐渐上增的趋势.IgA肾病患者临床、病理表现、治疗反应和预后均存在着显著的差异,其差异性的机制目前仍然不清楚.近年来越来越多的证据表明遗传因素在该病的易感性以及疾病的进程中起重要的作用,IgA肾病的分子遗传学研究逐渐成为国内外关注的研究领域.     

Role of macromolecular IgA in IgA nephropathy

Primary IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis, leading to progressive renal failure in almost one third of the patients. The disease is characterized by mesangial deposits of IgA. The pathogenesis of IgAN remains incompletely understood. The basic abnormality of this disorder lies within the IgA immune system rather than in the kidney. Elevated levels of IgA and IgA-containing complexes are found in sera of most patients with IgAN, but increased levels alone are not sufficient to develop IgAN. Therefore abnormal physicochemical properties of circulating IgA, such as size, charge, and glycosylation may play a role. This is supported by the presence of altered glycosylation of serum and mesangial IgA in patients with IgAN. Although the precise origin and nature of the mesangial IgA deposits are still uncertain, they contain at least in part macromolecular IgA, which may be derived from circulating IgA-containing complexes. Recently, novel insights have been obtained in the molecular composition of circulating high-molecular-weight IgA, which might include complexes with underglycosylated IgA1 and IgA-CD89 complexes. In this review various aspects of macromolecular IgA in relation to IgAN will be discussed.     

Proteinuria in IgA nephropathy

Clinicopathological data in 74 patients with IgA nephropathy were analyzed with special attention to level of proteinuria and its prognostic significance in this disease. Excretion rates exceeding 3 g per day (heavy), in the range of 1 to 2.9 g (moderate) and under 1 g per day (mild) each occurred in approximately equal proportions of patients. One-sixth of those with more than 1 g developed end-stage renal failure, while serum creatinine never exceeded 2 mg/dl in any with mild proteinuria. "Renal survival" (serum creatinine of 2 mg/dl or less) at five years after presentation was 100% in patients with persistently mild proteinuria, 87% in those whose protein excretion reached the moderate range, and 69% when heavy or nephrotic range proteinuria developed. Of significance, only rarely did mild proteinuria at presentation increase to higher levels. A correlation existed between level of protein excretion and severity of mesangial, segmental or global proliferation, glomerulosclerosis, podocyte effacement, interstitial infiltration, tubular atrophy and vascular sclerosis, even in patients with unimpaired renal function. Moderate or heavy proteinuria typically preceded the onset of hypertension and occurred prior to the development of renal insufficiency. Our results underscore magnitude of proteinuria as an early marker of glomerular damage in the prognosis of IgA nephropathy.     

Polymorphism in IgA nephropathy

Summary: IgA nephropathy (IgAN) is polyphormic in its clinical manifestation, course and prognosis. Patients with isolated IgA deposit in glomeruli tend to have a high incidence of macroscopic haematuria and carry a better prognosis. In contrast, patients with deposits of IgA and IgG and IgM have a higher incidence of nephrotic syndrome and hypertension. In parallel, patients with IgA and IgG and IgM tend to have more glomerulosclerosis and tubulointestitial lesions. Recently, the angiotensin converting enzyme (ACE) gene polymorphism and its association in disease risk provided interesting exploration leading us to speculate about a possible mechanism to explain the variation in the rate of progression of IgAN; although, the results are still controversial. The variability of plasma ACE concentration has been shown to be associated with an insertion/deletion polymorphism. The frequencies of ACE genotype in 177 Chinese patients with IgAN has been observed. We found that patients with IgAN showed a higher frequency of DD genotype than normal population. In contrast to the previous reports, we did not find any association between ACE genotype and the rate of progression of IgAN. As different genotypes of IL-1 receptor antagonist (IL-1 ra) are also responsible for the circulating levels of IL-1 ra, the polymorphism of IL-1 ra gene has been analyzed in 100 IgAN patients. There was no significant difference in the frequency of IL1RN*2 allele between normal subjects and IgAN. However, patients with recurrent macroscopic haematuria showed a higher carriage rate of IL1RN*2. Hereditable factors, in combination with a number of recognized environmental risk factors, are important determinants of the pathogenesis and natural history of IgAN. The notion that the gene polymorphism might be responsible for the clinical features and progression of IgAN is both intriguing and provocative. The lessons from previous multiple small size studies have produced conflicting results illustrating the need for observation of large numbers of cases in further studies to verify these observed associations.     

Prognosis in IgA nephropathy

Summary: IgA nephropathy it is now widely recognized as the most common glomerulonephritis causing end-stage renal failure (ESRF) in many parts of the world. Large series of patients have been analysed in an attempt to identify prognostic clinical and histological features. Increasingly the importance of stage specific analysis of such factors has been reflected in the literature. Such analysis suggests that if therapeutic trials are to be conducted in an attempt to improve prognosis in IgA nephropathy these will need to be organized on a multicentre basis under the auspices of an international organization.     

Neutrophils in IgA nephropathy

Summary: Neutrophil participation is prominent in proliferative forms of glomerulonephritis. They are recruited by antibody-mediated chemoattractant complement fragments. Monocyte and endothelial derived cytokines or adhesion molecules may also recruit these cells. In most situations of inflammation, neutrophils induce injury by the release of reactive oxygen radicals and their production of lysosomal proteolytic enzymes. the clinical importance of neutrophils in mediating glomerular injury in IgA nephropathy (IgAN) has often been downplayed, although it has been recognized that IgA is involved in the initiation of intracellular oxidative metabolism in normal neutrophils. That disordered neutrophil activation could be relevant to the pathogenesis of IgAN seems likely from their prominent infiltration in glomerular capillaries in the acute phase of primary IgAN, increased expression of complement 3 receptors on neutrophils from patients with IgAN, and increased oxidative metabolism of neutrophils in these patients. Furthermore, recent data revealed heat-aggregated forms of IgA prepared from patients with IgAN exert an up-regulatory effect on calcium mobilization, inositol triphosphate production, and oxidative metabolism in human neutrophils. Interestingly, the plasma level of E-selectin, mainly derived from activated vascular endothelial cells upon interaction with neutrophil, was elevated following synpharyngitic macrohaematuria in patients with IgAN. There was also a significant stepwise increase in circulating E-selectin associated with increased histopathologic severity in these patients. These data tend to support the notion that neutrophils could be activated in IgAN despite lack of acute clinical exacerbation and may potentially be participating in the inflammatory process of glomerular and interstitial injury.     

Immunotherapy in IgA nephropathy

Summary: The purpose of this presentation was to review the recent results of immunotherapy (i.e. corticosteroids, cyclosporine A and mizoribine), in patients with IgA nephropathy. We summarized the effects of corticosteroid therapy in patients with advanced stage of IgA nephropathy in our division. These patients were divided into steroid or non-steroid (anti-platelet and/or anti-coagulation drug) therapy group. The clinical findings, 6 years after renal biopsy, were observed in this study. Mean levels of urinary protein excretion in the steroid therapy group (11 patients; 3.42 g/day) were higher than those in the non-steroid therapy group (nine patients; 1.64 g/day) at the time of renal biopsy. The mean levels of creatinine clearance (CCr) in the steroid or non-steroid therapy group were 61.2 and 78.6 mL/min, respectively. Efficacy of steroid or non-steroid therapy was similar in patients with the advanced stage of IgA nephropathy, and it appeared that the steroid therapy was not effective for patients in the advanced stage of this disease. Cyclosporine A is a fungal peptide with immunoregulatory properties inhibiting activation of both T and B cells. Recently, a new immunosuppressive agent, mizoribine has been developed in Japan. Mizoribine has a suppressive effect on antibody formation via the direct inhibition of B cell function. Koshikawa et al. reported the effect of this drug in 158 patients with steroid-resistant nephrotic syndrome in multi-center studies in Japan. Mizoribine was administered orally at 150 mg/day for 24 weeks. Efficacy of treatment with mizoribine was marked compared with that with placebo in patients with IgA nephropathy and membranous nephropathy. At present, the authors are determining the clinicopathological effects of mizoribine in ddY mice, a spontaneous animal model of IgA nephropathy.     

MicroRNAs in IgA nephropathy

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. It is considered that the pathogenesis of IgAN involves the ‘multiple hit theory’ and the immune-inflammatory mechanism; however, these theories have certain limitations. The gold standard for diagnosing IgAN is still renal biopsy. Although renal biopsy is accurate, it is traumatic and is associated with some risks and limitations, so there is a need for non-invasive diagnostic methods. According to recent studies, microRNAs (miRNAs) play important roles in the occurrence and development of IgAN; thus, they provide the possibility of the noninvasive diagnosis of IgAN and also have some value in predicting prognosis. This review summarizes the current research status of miRNAs in the occurrence, development, diagnosis, and prognosis of IgAN. We also highlight some interesting and challenging points that require further study.     

Secondary IgA nephropathy

IgA nephropathy (IgAN) is the most common pattern of primary glomerulonephritis seen in the Western world. In the majority of cases the cause remains unknown. Cases of familial IgAN and secondary IgAN have been reported and these have provided insights into underlying genetic and environmental triggers for this common glomerular disease. Secondary IgAN is seen most commonly in patients with liver disease or mucosal inflammation, in particular affecting the gastrointestinal tract. A number of dietary and microbial antigens have been identified in circulating IgA immune complexes and mesangial IgA deposits, suggesting that environmental factors may play a role in the pathogenesis of IgAN. There is an increasing literature reporting associations between IgAN and other diseases. Whether these reports represent chance associations or genuine shared pathophysiology is discussed.